Galectin Therapeutics to Present at the H.C. Wainwright 9th Annual MASH Investor Conference
Rhea-AI Summary
Galectin Therapeutics (NASDAQ: GALT) will present at the H.C. Wainwright 9th Annual MASH Virtual Investor Conference on October 21, 2025.
Company presentation is scheduled for October 21, 2025 at 7:00 AM ET, with a live webcast and archived replay available on the company’s Events & Presentations page in Investors. Management attending includes Joel Lewis, CEO, and Khurram Jamil, M.D., CMO, who will be available for one-on-one meetings during the conference; interested investors should contact their H.C. Wainwright representative to arrange meetings.
Positive
- None.
Negative
- None.
News Market Reaction 2 Alerts
On the day this news was published, GALT gained 2.00%, reflecting a moderate positive market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $7M to the company's valuation, bringing the market cap to $340M at that time.
Data tracked by StockTitan Argus on the day of publication.
NORCROSS, Ga., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that the company management will participate in the H.C. Wainwright 9th Annual MASH Virtual Investor Conference, taking place October 21, 2025.
H.C. Wainwright 9th Annual MASH Investor Conference
Company presentation: October 21, 2025, at 7:00 AM ET
Webcast: here
The live and archived webcast will also be available on the Events & Presentations page in the investors section of the Company’s website.
Additionally, the Galectin management team, including Joel Lewis, Chief Executive Officer, and Khurram Jamil, M.D., Chief Medical Officer, will be available for one-on-one meetings during the conference. Interested investors should contact their representative at H.C. Wainwright.
About Galectin Therapeutics
Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. Galectin’s lead drug belapectin is a carbohydrate-based drug that inhibits the galectin-3 protein, which is directly involved in multiple inflammatory, fibrotic, and malignant diseases, for which it has Fast Track designation by the U.S. Food and Drug Administration. The lead development program is in metabolic dysfunction-associated steatohepatitis (MASH) with cirrhosis, the most advanced form of MASH-related fibrosis. Liver cirrhosis is one of the most pressing medical needs and a significant drug development opportunity. Additional development programs are in treatment of combination immunotherapy for advanced head and neck cancers and other malignancies. Advancement of these additional clinical programs is largely dependent on finding a suitable partner. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. Additional information is available at www.galectintherapeutics.com.
Company Contact:
Jack Callicutt, Chief Financial Officer
(678) 620-3186
ir@galectintherapeutics.com
Investors Relations Contact:
Kevin Gardner
kgardner@lifesciadvisors.com
Galectin Therapeutics and its associated logo is a registered trademark of Galectin Therapeutics Inc. Belapectin is the USAN assigned name for Galectin Therapeutics’ galectin-3 inhibitor belapectin.
FAQ
When will Galectin Therapeutics (GALT) present at the H.C. Wainwright MASH conference?
How can investors watch the GALT presentation on October 21, 2025?
Who from Galectin Therapeutics will speak at the H.C. Wainwright MASH conference?
Can investors schedule one-on-one meetings with GALT management at the October 21, 2025 conference?
Where will the archived webcast of the Galectin Therapeutics presentation be posted?
